Annalisa Jenkins
CIK: 0001639481
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Mar 31, 2026SKYE
Skye Bioscience, Inc.
Award(A)DirectStock Option (Right to Buy)
75K shares- - Feb 26, 2026MREO
Mereo BioPharma Group plc
Award(A)DirectShare Options (Right to buy)
66K shares- - Feb 26, 2026MREO
Mereo BioPharma Group plc
Award(A)DirectDeferred Restricted Stock Units
106.8K shares- - Feb 6, 2026SKYE
Skye Bioscience, Inc.
Award(A)DirectStock Option (Right to Buy)
35K shares- - Jun 12, 2025CMPS
COMPASS Pathways plc
Award(A)DirectShare Option (Right to Buy)
26K shares- - Feb 24, 2025SKYE
Skye Bioscience, Inc.
Award(A)DirectStock Option (Right to Buy)
35K shares- - Feb 5, 2025MREO
Mereo BioPharma Group plc
Award(A)DirectDeferred Restricted Stock Units
15.2K shares- - Feb 5, 2025MREO
Mereo BioPharma Group plc
Award(A)DirectShare Options (Right to buy)
55K shares- - Oct 28, 2024SKYE
Skye Bioscience, Inc.
Award(A)DirectStock Option (Right to Buy)
70K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 31, 2026 |  SKYE Skye Bioscience, Inc. | Award(A) Stock Option (Right to Buy) | 75,000 | - | - | Direct |
| Feb 26, 2026 |  MREO Mereo BioPharma Group plc | Award(A) Share Options (Right to buy) | 66,000 | - | - | Direct |
| Feb 26, 2026 | MREO Mereo BioPharma Group plc | Award(A) Deferred Restricted Stock Units | 106,848 | - | - | Direct |
| Feb 6, 2026 | SKYE Skye Bioscience, Inc. | Award(A) Stock Option (Right to Buy) | 35,000 | - | - | Direct |
| Jun 12, 2025 |  CMPS COMPASS Pathways plc | Award(A) Share Option (Right to Buy) | 26,000 | - | - | Direct |
| Feb 24, 2025 | SKYE Skye Bioscience, Inc. | Award(A) Stock Option (Right to Buy) | 35,000 | - | - | Direct |
| Feb 5, 2025 | MREO Mereo BioPharma Group plc | Award(A) Deferred Restricted Stock Units | 15,243 | - | - | Direct |
| Feb 5, 2025 | MREO Mereo BioPharma Group plc | Award(A) Share Options (Right to buy) | 55,000 | - | - | Direct |
| Oct 28, 2024 | SKYE Skye Bioscience, Inc. | Award(A) Stock Option (Right to Buy) | 70,000 | - | - | Direct |
1-9 of 9 transactions
About Jenkins Annalisa
Jenkins Annalisa (SEC CIK 0001639481) files insider reports with the SEC as Director of Skye Bioscience, Inc. (SKYE), Director of Mereo BioPharma Group plc (MREO) and Director of COMPASS Pathways plc (CMPS).
Signal8 holds 7 ownership filings by Jenkins Annalisa, all Form 4s, filed between Oct 30, 2024 and Apr 2, 2026. Those filings report 9 transactions, from Oct 28, 2024 to Mar 31, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Jenkins Annalisa's filings is in SAN DIEGO, CA.
Recent filings by Jenkins Annalisa
- Mar 31, 2026: Grant or award of SKYE derivative securities (Form 4, code A).
- Feb 26, 2026: Grants or awards of MREO derivative securities (2 lines, Form 4, code A).
- Feb 6, 2026: Grant or award of SKYE derivative securities (Form 4, code A).
- Jun 12, 2025: Grant or award of CMPS derivative securities (Form 4, code A).
- Feb 24, 2025: Grant or award of SKYE derivative securities (Form 4, code A).
Other insiders filing for Skye Bioscience, Inc. (SKYE)
- Schwab Andrew J., Director
- 5AM Partners VII, LLC, 10% Owner
- DHILLON PUNIT, Chief Executive Officer
- Sharp John P, Chief Financial Officer
- Smith Karen L., Director
- Twitty Christopher, Chief Scientific Officer